Japan Medical Device Corporation (Headquarters: Shinagawa-ku, Tokyo, Representative Director: OKANO Takafumi, hereinafter referred to as “JMD”) has been participating as a member of “Overcoming the Heart Failure Pandemic by Innovative Integration of Multi-Scale Cardiac Simulator and Large-Scale Clinical Data”, one of the programs to accelerate the achievement of the MEXT supercomputer “Fugaku” since April 1, 2021.
This time, CTO Chiba et al. have succeeded in an ultra-large-scale cardiac simulation using the supercomputer “Fugaku” using the computing resources of about 3.83 million cores, which is about 5.4 times the scale of the “Kei” computer. Fugaku has made it possible to perform beat analysis by combining coarse-grained molecular simulations and heart simulations, and we have taken a major step toward elucidating the pathogenesis of dilated cardiomyopathy and hypertrophic cardiomyopathy. JMD will work together with UT-Heart Inc. and other cooperating institutions to conduct this research and strive for the success of this research. Through this research, we will contribute to the early detection and treatment of heart failure patients and contribute to the improvement of the QOL (quality of life) of all humankind.
|【Inquiries regarding this release】|
Japan Medical Device Corporation
Person in charge: CHIBA Shuichi